HomeCompareMPSFF vs ABBV

MPSFF vs ABBV: Dividend Comparison 2026

MPSFF yields 1052.63% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MPSFF wins by $29512389.18M in total portfolio value
10 years
MPSFF
MPSFF
● Live price
1052.63%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29512389.28M
Annual income
$24,865,533,772,207.38
Full MPSFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MPSFF vs ABBV

📍 MPSFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMPSFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MPSFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MPSFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MPSFF
Annual income on $10K today (after 15% tax)
$89,473.68/yr
After 10yr DRIP, annual income (after tax)
$21,135,703,706,376.27/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MPSFF beats the other by $21,135,703,685,320.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MPSFF + ABBV for your $10,000?

MPSFF: 50%ABBV: 50%
100% ABBV50/50100% MPSFF
Portfolio after 10yr
$14756194.69M
Annual income
$12,432,766,898,489.57/yr
Blended yield
84.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MPSFF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MPSFF buys
0
ABBV buys
0
No recent congressional trades found for MPSFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMPSFFABBV
Forward yield1052.63%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$29512389.28M$102.3K
Annual income after 10y$24,865,533,772,207.38$24,771.77
Total dividends collected$29159831.22M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MPSFF vs ABBV ($10,000, DRIP)

YearMPSFF PortfolioMPSFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$115,963$105,263.16$11,550$430.00+$104.4KMPSFF
2$1,264,889$1,140,808.24$13,472$627.96+$1.25MMPSFF
3$12,982,935$11,629,504.04$15,906$926.08+$12.97MMPSFF
4$125,449,028$111,557,287.82$19,071$1,382.55+$125.43MMPSFF
5$1,141,645,861$1,007,415,400.94$23,302$2,095.81+$1141.62MMPSFF
6$9,789,747,608$8,568,186,536.38$29,150$3,237.93+$9789.72MMPSFF
7$79,141,579,327$68,666,549,386.16$37,536$5,121.41+$79141.54MMPSFF
8$603,475,154,069$518,793,664,189.69$50,079$8,338.38+$603475.10MMPSFF
9$4,342,855,615,350$3,697,137,200,495.55$69,753$14,065.80+$4342855.55MMPSFF
10$29,512,389,280,631$24,865,533,772,207.38$102,337$24,771.77+$29512389.18MMPSFF

MPSFF vs ABBV: Complete Analysis 2026

MPSFFStock

RevoluGROUP Canada Inc., through its subsidiaries, provides technology solutions in the Americas, Europe, and internationally. The company offers RevoluPAY, the company's flagship Apple and Android multinational remittance app; RevoluVIP, a members only travel club; RevoluCHARGE, a pay-as-you go mobile top-up application; RevolUTILITY, a utility bills payment solution; RevoluREALTY, a solution for the payment of real estate related transactions, forex settlement, and closing fees to multiple beneficiaries; and RevoluMED, a solution for healthcare appointment scheduling, RX payment, pharmacy payments, medical insurance, insurance copay, and other financial aspects related to the healthcare industry. It also provides RevoluFIN, which offers bridge loans and factoring to corporations; RevoluEGAME for online video gaming, and selection and payment of mobile/console-based games and in-game play; RevoluESPORTS for eSports sector; RevoluSEND, a remittance platform; RevoluEX, a digital currency exchange solution; RevoluTRANSFER, an online money transfer solution; and RevoluPOS, a point of sale platform. In addition, the company engages in the online travel agency and digital media marketing businesses that cover travel marketing, electronic reservations, travel membership sales, and online booking solutions. It deploys technology solutions in the online travel, vacation forex, money remittance, mobile payment apps, mobile phone top-up, utility bill and healthcare payments, e-gaming, e-sports, online credits and gifts cards, real estate payments, blockchain security, invoice factoring and alternative lending, and POS merchant provider in personal and corporate leisure sectors. The company was formerly known as CUV Ventures Corp. and changed its name to RevoluGROUP Canada Inc. in November 2019. RevoluGROUP Canada Inc. was incorporated in 1980 and is headquartered in Burnaby, Canada.

Full MPSFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MPSFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MPSFF vs SCHDMPSFF vs JEPIMPSFF vs OMPSFF vs KOMPSFF vs MAINMPSFF vs JNJMPSFF vs MRKMPSFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.